Bioquímica Médica y Biología Molecular e Inmunología
URI permanente para esta comunidadhttps://hdl.handle.net/11441/10989
Examinar
Examinando Bioquímica Médica y Biología Molecular e Inmunología por Agencia financiadora "Cancer Research Foundations of Radiumhemmet"
Mostrando 1 - 1 de 1
- Resultados por página
- Opciones de ordenación
Artículo NK cells and solid tumors therapeutic potential and persisting obstacles(BMC, 2022-11-01) Tong, Le; Jiménez Cortegana, Carlos; Tay, Apple H.M.; Wickström, Stina; Galluzzi, Lorenzo; Lundqvist, Andreas; Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología; 2019 Laura Ziskin Prize in Translational Research; Cancer Research Foundations of Radiumhemmet; Dept. of Radiation Oncology at Weill Cornell Medicine (New York, US); donations from Promontory (New York, US); Functional Genomics Initiative (New York, US); Leukemia and Lymphoma Society (LLS); Luke Heller TECPR2 Foundation (Boston, US); Lytix Biopharma (Oslo, Norway); NIH/NCI; Noxopharm (Chatswood, Australia); Onxeo (Paris, France); Ricerchiamo (Brescia, Italy); romontory (New York, US); Sotio a.s. (Prague, Czech Republic); Stand Up to Cancer (SU2C); Swedish Cancer Society; Swedish Childhood Cancer Foundation; US DoD BCRPNatural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic activity, have recently attracted attention as potential anticancer therapeutics. While NK cells mediate encouraging responses in patients with leukemia, the therapeutic effects of NK cell infusion in patients with solid tumors are limited. Preclinical and clinical data suggest that the efficacy of NK cell infusion against solid malignancies is hampered by several factors including inadequate tumor infiltration and persistence/activation in the tumor microenvironment (TME). A number of metabolic features of the TME including hypoxia as well as elevated levels of adenosine, reactive oxygen species, and prostaglandins negatively affect NK cell activity. Moreover, cancer-associated fibroblasts, tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells actively suppress NK cell-dependent anticancer immunity. Here, we review the metabolic and cellular barriers that inhibit NK cells in solid neoplasms as we discuss potential strategies to circumvent such obstacles towards superior therapeutic activity.